Information Provided By:
Fly News Breaks for May 14, 2018
May 14, 2018 | 09:17 EDT
Stifel analyst Rick Wise commented on the "60 Minutes" story regarding Boston Scientific transvaginal mesh products and associated lawsuits, calling the report "unsettling...but likely overstated." He notes that the company has reached or is near settlement on 47,500 of the known 49,500 mesh legal claims, has a $1.5B legal reserve for the matter and has said it expects the majority of the remaining mesh claims to be resolved in 2018. Wise keeps a Buy rating and $33 price target on Boston Scientific shares.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.